Avenacy debuts generic Integrilin for Injection
Avenacy, a specialty pharmaceutical company that supplies injectable medications, launched Eptifibatide for Injection, a generic for Merck’s Integrilin.
Eptifibatide for Injection is indicated for use in acute coronary syndrome and percutaneous coronary intervention.
Avenacy’s Eptifibatide for Injection is available in a 75 mg/100 ml single-dose vial. In line with the company’s mission to champion patient safety and streamline patient care, the medication will feature highly differentiated packaging and labeling to support accurate medication selection.
[Read more: Global generic drugs market to reach $671.5B by 2030, report finds]
The company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.
Eptifibatide for Injection had a market value of approximately $8.3 million for the 12 months ending in June 2023, per IQVIA.
Approved indications for the medication include:
- Acute Coronary Syndrome: Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction in patients with ACS (unstable angina/non-ST-elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention.
- Percutaneous Coronary Intervention: Eptifibatide injection is indicated to decrease the rate of a combined endpoint of death, new MI, or need for urgent intervention in patients undergoing PCI, including those undergoing intracoronary stenting.
[Read more: Challenges continue, but generics companies see a bright future with] biosimilars]